The estimates are currently that in the United States, are approximately 100,000 people every year that die from adverse drug reactions. There's also estimates that many drugs work in less than half of the people that actually take them. And with that many people that are actually dying from these adverse drug reactions and the amount of people that are not getting the full and beneficial effects of the drugs makes us a huge, really a big burden to our health care system, as well as to the individuals who either, you know, have a bad reaction to a drug or are taking drugs that are ineffective during that time when they're actually taking them. Research is really focused on trying to understand how to improve the way we use drug therapies that are currently being used. There's a lot of variability between the way people respond to drugs. Part of that is because of the genetics, so the genes we inherit from our parents. And with some drugs, we can actually use those genetic markers as a way to predict which is going to be the best drug for a particular individual. Combining the genetics and the pharmacology, and what we call pharmacogenetics or pharmacogenomics is the combination that we can use to really help health care providers choose the best drug for the individual, so we can minimize the toxicities and side effects but maximize the effectiveness. So there are a lot of benefits that this research pro. Adverse drug events are a big problem in the health system, and we have a lot of pharmacogenomic information that we've called and learned over the course of decades, which have yet to translate into clinical care. And doctor Score, as head of the Pharmacogenomics project within the Indiana University Precision Health Initiative, and the Indiana Institute of Personalized Medicine, has really been transformational bringing that data to the clinical practice. Before this project through the Precision Health Initiative, we didn't have the ability to order pharmacogenomic testing directly in the electronic Health. And we certainly didn't have the ability to have clinical decision support implemented in the health record, so that when we go to prescribe drug that we know that we're giving the right dose at the right time to patient. There's so many ways that this research has made a difference in our community. We've been able to implement some pharmacogenomics testing statewide, which has been very new to the Indiana and our Hoosiers, and it's really nice to be able to take those things out to the community. So it's not just those patients that are here being treated at the Academic Health Center, but all those patients living in more rural underserved areas are also getting the benefits of this research. I got involved in this project to be a voice for the unseen and the unheard. And to hopefully increase awareness about some of the barriers racial and ethnic minorities face when participating in research and clinical trials. We should care about this research. Everyone should care. We should care that equal access to health care and effective treatments exist for all populations. We are all interconnected and what adversely affects one population will certainly have some effect on the population as a whole.